LFT (Spectrophotometry, Electromechanical Clot Detection, CMIA)

AST (SGOT) U/L

ALT (SGPT) U/L

GGTP U/L

Alkaline Phosphatase (ALP) U/L

Bilirubin, Total mg/dL

Bilirubin, Direct mg/dL

Bilirubin, Indirect mg/dL

Protein, Total g/dL

Albumin g/dL

A:G Ratio

PROTHROMBIN TIME

Mean Normal Prothrombin Time (PT)

Patient value

Prothrombin Ratio ( PR) sec (10.80-15.60)

International Normalized Ratio (INR) sec (0.90-1.20)

HBsAg Reactive / Non reactive

1. All Reactive results for HBsAg are tested additionally by Specific antibody Neutralization assay .

For further confirmation Molecular assays are recommended

2. Discrepant results or HBsAg may be observed during pregnancy, patients receiving mouse

monoclonal antibodies for diagnosis or therapy & mutant forms of HBsAg

3. For diagnostic purposes, results should be used in conjunction with clinical history and

other hepatitis markers for Acute or Chronic infection

4. For monitoring HBsAg levels, Quantitative HBsAg assay is recommended

5. INR is the parameter of choice in monitoring adequacy of oral anticoagulant

therapy. Appropriate therapeutic range varies with the disease and treatment

intensity

6. Enhanced liver fibrosis (ELF) test is used to evaluate liver fibrosis in patients with

suspected chronic liver disease due to Viral Hepatitis B & C, Alcoholic liver disease and Non

alcoholic fatty liver disease

7. Results should be clinically correlated

8. Test conducted on Serum & Citrated plasma